1. In Vivo

Rating the Japanese

Long resistant to consolidation, Japan's drug industry is now beginning to hurt too much to ignore the possibility. Yoshio Yano of Japan's International Pharma Consulting, rates the companies in terms of their ability to internationalize--and, for those who can't, their likelihood to become part of another company.

Long resistant to consolidation, Japan's drug industry is now beginning to hurt too much to ignore the possibility, notes Yoshio Yano of Japan's International Pharma Consulting. So far, most of the M&A activity has focused on the diversified industrial companies and on the smaller pharmaceutical pure-plays. Asahi Breweries Ltd. , for example, discontinued its undersized ethical drug business and sold its majority stake in Torii Pharmaceutical Co. Ltd. to Japan Tobacco Inc. [See Deal]. Kanebo Ltd. sold its drug business to Akzo Nobel NV 's Organon Group [See Deal]. Mitsubishi Chemical Corp. merged its drug unit into Tokyo Tanabe Co. Ltd.[See Deal].

The economic pain is simply too severe for many Japanese firms to continue to bear it alone, argues Yano. The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By Jo Shorthouse

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By David Wild

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.